People · Operator
Named in public records as an officer, director or promoter · active 2008–2013 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Portola Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $158.1M | $315.8M | 2008 |
| Allakos Inc. | — | Biotechnology | Series D+ | $128.1M | $4.1B | 2012 |
| Trevena Inc | — | Pharmaceuticals | Series C | $77.5M | $2.1B | 2010 |
| Aerovance Inc | — | Biotechnology | Series B | $22.5M | $19.8M | 2009 |
| Zelos Therapeutics Inc | — | Pharmaceuticals | Series A | $17.8M | $75.0M | 2009 |
Farah Champsi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Farah Champsi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| James Topper | 1 | 12 |
| Russell Hirsch | 1 | 10 |
| David Solomon | 1 | 8 |
| Robert Garland | 1 | 7 |
| JEFF BIRD | 1 | 7 |
| Nicholas Galakatos | 1 | 6 |
| Joseph Zakrzewski | 1 | 6 |
| Jean George | 1 | 6 |
| Christopher Mirabelli | 1 | 6 |
| Mark Perry | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Peter Moldt | 1 | 6 |
| John McKearn | 1 | 6 |
| Alan Frazier | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Douglas E. Williams | 1 | 4 |
| Ralph Snyderman | 1 | 4 |
| Paul Walker | 1 | 4 |
| Brian MacDonald | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.